BioStem Technologies (OTCMKTS:BSEM - Get Free Report) announced its quarterly earnings data on Monday. The company reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.31, Zacks reports. The firm had revenue of $10.29 million for the quarter, compared to the consensus estimate of $86.69 million.
BioStem Technologies Stock Performance
Shares of BioStem Technologies stock traded down $0.48 during trading hours on Friday, reaching $12.25. The company's stock had a trading volume of 96,304 shares, compared to its average volume of 66,340. BioStem Technologies has a one year low of $6.77 and a one year high of $28.26. The company's 50 day simple moving average is $11.31 and its 200 day simple moving average is $13.74. The stock has a market cap of $204.61 million, a P/E ratio of 18.01 and a beta of 0.09.
About BioStem Technologies
(
Get Free Report)
BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.
Recommended Stories
Before you consider BioStem Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioStem Technologies wasn't on the list.
While BioStem Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
